miR-143-3p Inhibits Aberrant Tau Phosphorylation and Amyloidogenic Processing of APP by Directly Targeting DAPK1 in Alzheimer’s Disease. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.